DexCom’s Q2 2026: Revenue Surges, Guidance Gets a Lift, and a Stelo‑Powered Glass Half‑Full Outlook

Second Quarter Highlights

DexCom, Inc. (DXCM) delivered a robust Q2 2026, with revenue of $1.308 billion, up 13% from a year earlier on a reported basis and 12% on an organic basis. The U.S. market grew 11% while international revenue rose 19% (16% on an organic basis), underscoring continued global CGM adoption and a favorable mix shift toward higher‑margin territories.

Profitability followed the revenue tempo. GAAP operating income reached $318.3 million, or 24.3% of revenue, a substantial expansion of about 590 basis points versus the second quarter of 2025. On a non‑GAAP basis, operating income stood at $328.3 million, or 25.1% of revenue, matching the same 590‑basis‑point improvement year over year. Gross profit also climbed: GAAP gross profit was $830.0 million (63.4% of revenue) and non‑GAAP gross profit was $838.5 million (64.1% of revenue).

These results set a tone of improving operating leverage, with margins moving in step with top‑line growth and a continued emphasis on the durability of DexCom’s CGM ecosystem.

Strategic Highlights

• DexCom hosted its 2026 Investor Day, outlining market opportunities, strategy, innovation efforts, and a new long‑term financial outlook through 2030.
• The company reported positive results from the CONNECT trial, showing that DexCom CGM use among people with type 2 diabetes not using insulin yielded meaningful and statistically significant improvements in glucose control versus routine care.
• Initiated the launch of a reimagined Stelo app experience, aiming to deliver more consumer‑friendly insights, AI‑driven features, and enhanced food logging for Stelo users.

Executive Commentary

“During the quarter, we had the opportunity to host many of you at our 2026 Investor Day, where we highlighted our substantial market opportunity and introduced a new long‑term financial outlook through 2030,” said Jake Leach, Dexcom’s president and CEO. “This quarter’s performance and the successful outcomes from our CONNECT trial reinforce our confidence in the path ahead and position us well to deliver on our long‑range plan.”

Guidance and Revenue Forecast

DexCom raised the midpoint of its fiscal 2026 revenue guidance and increased the outlook for non‑GAAP gross profit margin, non‑GAAP operating margin, and adjusted EBITDA margin. The company now targets revenue of $5.18–$5.25 billion for 2026, implying approximately 11–13% growth. The updated framework also embeds a non‑GAAP gross margin around 64%, non‑GAAP operating margin in the ~23.5–24% range, and an adjusted EBITDA margin near 31.5–32%.

From an earnings perspective, the upper‑single to low‑double‑digit growth in revenue should support a healthier EPS trajectory on both GAAP and non‑GAAP bases, though the company does not publish an explicit EPS figure in this excerpt. Investors will be watching how the EPS consensus for the full year compares to this revised outlook, and whether a potential earnings surprise materializes as the year unfolds.

What This Might Portend for DexCom and Sector Peers

The beat-to-beat cadence on margins matters as DexCom shows that top‑line growth can translate into sustainable profitability gains. The turn toward higher profitability is particularly notable given the timing of strategic investments—Investor Day disclosures, the CONNECT trial validation, and the Stelo app refresh—all of which hint at a broader value proposition beyond device sales alone. In short, DexCom is layering a stronger base of recurring value into its business model: better data, stronger app ecosystem, and a clearer runway for premium pricing on a differentiated CGM offering.

For peers in the CGM and broader digital health space, the narrative here is twofold. First, product depth and downstream monetization (software, insights, and platform effects) increasingly matter alongside hardware growth. Second, clinical validation—whether via trials like CONNECT or robust real‑world performance—can unlock broader addressable markets, especially in patient segments previously underpenetrated (e.g., type 2 diabetes patients not on insulin).

Outlook for the Sector

DexCom’s revenue trajectory and margin discipline may raise the bar for peers pursuing a similar blend of device sales and software‑driven value. The emphasis on AI‑driven insights and consumer‑grade app experiences signals a shift toward more user‑friendly platforms that can improve adherence and outcomes, potentially elevating the sector’s overall revenue forecast as payer and provider ecosystems adapt to value‑based care incentives.

Investors will likely monitor how DexCom translates this quarter’s momentum into sustainable earnings growth, whether EPS margins can sustain current levels, and how the company manages R&D and go‑to‑market investments in a competitive landscape. The risk, of course, lies in execution and in the broader macro climate, but the early signs suggest DexCom is steering toward a durable, software‑enabled growth arc rather than a one‑time margin uptick.

Bottom Line

Q2 2026 confirms DexCom’s ability to convert volume growth into meaningful profitability, with a refreshed revenue forecast and an upgraded margin outlook. The combination of a strong geographic mix, validated clinical data, and a consumer‑oriented software strategy may extend DexCom’s growth runway while setting a benchmark for peers pursuing a similar model. For those tracking EPS trajectories, earnings surprises, and EPS consensus moving targets, the throughline is clear: DexCom is building a platform with multiple value levers that could sustain above‑trend growth into 2027 and beyond.